Sumanta Kumar Pal, MD, FASCO, joins Rohit Gosain, MD, and Rahul Gosain, MD, to discuss risk stratification and treatment practices for patients with localized kidney cancer following surgery.
Fruquintinib/Sintilimab Meets PFS End Point in Advanced or Metastatic RCC
Fruquintinib plus sintilimab improved PFS, ORR, and DOR compared with axitinib or everolimus monotherapy in RCC in the phase 2/3 FRUSICA-2 trial.
Traversing the Complexities of Non-Clear Cell Renal Cell Carcinoma
A brief overview of the current RCC landscape was provided in the most recent Oncology Decoded podcast.
Avelumab Combo Improves Long-Term Efficacy Vs Sunitinib in Advanced RCC
Longer progression-free survival and more enduring responses occurred with avelumab/axitinib vs sunitinib in the phase 3 JAVELIN Renal 101 trial.
Expanding and Advancing the Future of Renal Cell Carcinoma Treatment
Eric Jonasch, MD, believes that the Kidney Cancer Research Consortium may broaden their reach to provide care to many different groups of patients.
PROs Comparable with Tivozanib Alone or With Nivolumab in Advanced Clear Cell RCC
The TiNivo-2 trial found comparable PROs with tivozanib plus nivolumab vs tivozanib monotherapy in advanced clear cell RCC.
Cabozantinib Combo Yields Sustained PFS at Follow-Up in Advanced RCC
Efficacy results remained consistent with previous reports in the cabozantinib, nivolumab, and ipilimumab arm for patients with advanced renal cell carcinoma.